
Sign up to save your podcasts
Or
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
4.5
236236 ratings
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
43,929 Listeners
30,940 Listeners
32,131 Listeners
26,161 Listeners
59,376 Listeners
4,127 Listeners
9,547 Listeners
9,525 Listeners
572 Listeners
14,388 Listeners
6,240 Listeners
5,090 Listeners
405 Listeners
74 Listeners
1,836 Listeners
4,755 Listeners
2,139 Listeners
80 Listeners
425 Listeners
236 Listeners
1,223 Listeners
265 Listeners
232 Listeners
434 Listeners
148 Listeners
367 Listeners
331 Listeners
31 Listeners
96 Listeners
1,587 Listeners
77 Listeners
256 Listeners
250 Listeners